
# Modular synthesis of 1,2-azaborines via ring-opening BN-isostere benzannulation

Hairong Lyu<sup>1</sup>, Thomas H. Tugwell<sup>2</sup>, Zhijie Chen<sup>1</sup>, Garrett A. Kukier<sup>3</sup>, Aneta Turlik<sup>3</sup>, Yifei Wu<sup>1</sup>, K. N. Houk<sup>3\*</sup>, Peng Liu<sup>2\*</sup>, and Guangbin Dong<sup>1\*</sup>

1Department of Chemistry, University of Chicago, Chicago, IL 60637, USA 2Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA 3Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA \*Corresponding author, e-mail: gbdong@uchicago.edu \*Corresponding author, e-mail: pengliu@pitt.edu \*Corresponding author, e-mail: houk@chem.ucla.edu

1,2-Azaborines represent a unique class of benzene isosteres that holds great potential for various applications. However, it remains a long-standing challenge to prepare monocyclic 1,2-azaborines in an efficient and modular manner. Here we report a straightforward method to directly access diverse multi-substituted 1,2-azaborines from readily available cyclopropyl imines/ketones and dibromoboranes under relatively mild conditions. The reaction is scalable, shows a broad substrate scope, and tolerates a range of functional groups. The utility of this method is demonstrated in the concise syntheses of BN isosteres of a PD-1/PD-L1 inhibitor and pyrethroid insecticide bifenthrin. Combined experimental and computational mechanistic studies suggest that the reaction pathway involves boron-mediated cyclopropane ring-opening and base-mediated elimination, followed by an unusual low-barrier  $6\pi$ -electrocyclization accelerated by the BN/CC isomerism.

Due to the prevalence of arenes in small-molecule drugs, incorporating arene isosteres or bioisosteres has become an emerging strategy in medicinal chemistry for identifying candidates of enhanced performance without substantially altering structures of lead compounds<sup>1</sup>. 1,2-Azaborines, a class of boron-nitrogen heterocycles with substantial aromaticity, are viewed as unique BN-isosteres of benzene (Fig. 1A)<sup>2,3,4,5,6</sup>. They are generally more polar than benzene, leading to more localized electron distributions and better aqueous solubility<sup>7</sup>. Comparing to the original carbonaceous compounds, improved biological activity and bioavailability have been observed with their 1,2-azaborine analogues <sup>8,9,10,11,12,13</sup>. For example, shown in a 2017 report by Liu, the replacement of a phenyl group with a simple 1,2-azaborine moiety in a CDK2 inhibitor led to 2-4-fold increase of efficacy<sup>7</sup>. Similarly, Janssen Pharmaceuticals disclosed systematic *in vitro* and *in vivo* profiling of 1,2-azaborine analogues of several drug candidates, in which comparable or even better biological activity and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties have been observed<sup>14</sup>. These studies further suggest that 1,2-azaborines are stable under physiological, mildly basic, or oxidative conditions, serving as viable pharmacophores<sup>15</sup>.




**Fig. 1** | **Synthetic methods to access 1,2-azaborines. a.** Isosterism between benzene and 1,2-azaborine as well as their applications in medicinal chemistry. **b.** Representative syntheses of monocyclic 1,2-azaborines. TMS, trimethylsilyl. **c.** This work: a two-step or one-pot modular synthesis of multi-substituted 1,2-azaborines from simple building blocks. DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene.

Despite the great promise of using 1,2-azaborines as arene bioisosteres in drug discovery, only a limited number of bioactive BN-analogues have been reported to date, because it is still not a trivial task to access multi-substituted 1,2-azaborines<sup>2-6</sup>. In particular, unlike those in a fused polyaromatic system<sup>2,4</sup>, preparation of monocyclic 1,2-azaborines remains a substantial challenge<sup>3</sup>. The state-of-art synthesis employed allyl Molander salt and allyl amine as substrates to access *B*-alkoxy-1,2-azaborines in 25% yield over four steps, featured by a ring-closing metathesis with Schrock's catalyst and a Pd-catalyzed dehydrogenative aromatization (Fig. 1b)<sup>16</sup>. While this represents a remarkable improvement from the prior approaches<sup>17,18,19</sup>, extension of this strategy to directly prepare C-substituted 1,2-azaborines has been elusive. For instance, synthesis of C6-substituted 1,2-azaborines required an overall six-step sequence<sup>20</sup>. Alternatively, Braunschweig et al. disclosed a distinct approach to access poly-substituted 1,2-azaborines through either insertion of a nitrene into boroles (generated from a divinyl lithium intermediate)<sup>21</sup> or via a Rh-catalyzed/mediated cyclization between iminoboranes and alkynes<sup>22,23</sup>; these reactions show limited scopes with moderate yield. To harness the full potential of the BN/CC isomerism for medicinal chemistry research, we recognized that it would be necessary to conceive of a more direct BN-benzannulation strategy to access monocyclic 1,2-azaborines. Ideally, this strategy can 1) use easily accessible substrates,

2) operate under mild conditions, 3) tolerate a broad range of functional groups, 4) give good overall yield, 5) avoid expensive noble metals, 6) be easily scalable, and 7) be modular to access multi-substituted 1,2-azaborines with diverse structures in a straightforward manner. Here, we describe the development of a general 1,2-azaborine-synthesis method that meets all the above criteria (Fig. 1c).

#### **Results and discussion**


**Reaction discovery and optimization.** From the outset, we questioned whether 1,2-azaborines could be synthesized from readily available cyclopropyl imines and a boron electrophile via a "ring-opening-thenrebound" strategy <sup>24</sup>. It was initially hypothesized that a tandem boron-mediated C-C bond cleavage<sup>25</sup>/reductive C-B bond formation should generate the six-membered BN-heterocycle, which then gives the 1,2-azaborines after oxidative aromatization (Fig. 2a). While this proposal was indeed feasible (for details, see Supplementary Fig. S1), to our surprise, a more straightforward and *redox-neutral* method to prepare 1.2-azaborines was realized simply by treating the ring-opened intermediate with a base in a one-pot manner (Fig. 2b). For example, when cyclopropyl phenyl imine 1a was employed as the model substrate, its reaction with (o-tolyl)BBr<sub>2</sub> 2a in the presence of 10 mol% ZnBr<sub>2</sub> at 60 °C for 4 h, followed by in situ addition of DBU, gave the desired 1,2-azaborine 3a in 84% yield. This protocol avoids oxidation and reduction and is easy to operate. The role of the Lewis acid was likely to activate the imine/dibromoborane adduct in order to promote the cyclopropane ring-opening. Among various Lewis acids examined, ZnBr<sub>2</sub> proved to be optimal (Fig. 2b). While Zn(OTf)<sub>2</sub> and BF<sub>3</sub> also offered good yield, other Lewis acids were less efficient. On the other hand, DBU was found to be the most suitable base; in contrast, weaker amines or inorganic bases were not effective for this transformation (for details, see Supplementary Information).




**Fig. 2** | **Proposed strategy and reaction discovery. a.** The original proposal involved a tandem Lewis acid-catalyzed boronmediated C–C bond cleavage/reductive C–B bond formation, followed by an oxidative aromatization. **b.** A redox-neutral condition was discovered with  $ZnBr_2$  as the optimal Lewis acid; upon ring opening of the cyclopropane, treatment with DBU in situ directly gave the desired 1,2-azaborine in good yield.

Substrate scope and synthetic applications. Given that (a) cyclopropyl imines/ketones are readily accessible from the corresponding carboxylic acid derivatives and (b) dibromoboranes can be in situ generated from BBr3 and silanes, the scope of the reaction appears to be quite broad (Fig. 3). First, diverse anilines can efficiently condense with cyclopropyl ketones, which all generated the desired 1,2,6trisubstituted 1,2-azaborines in good yields. The reaction temperature was increased to 80 °C for some challenging substrates to enhance the overall efficiency. In addition, alkylamine-derived products can also be produced efficiently (3p-3y and 3aw). Moreover, both aryl and alkyl-substituted dibromoboranes, including the one derived from  $\alpha$ -pinene (**3ag**), were suitable coupling partners. Notably, a *B*-silylmethyl 1.2-azaborine (3ao) was effectively obtained and the silvl group could serve as a handle for further functionalization. Furthermore, various C6-substitutents, including aryl, alkenyl, and alkyl groups, can be installed. It is noteworthy that the 1,2-azaborine with alkyl substituents at both C6 and N1 positions (3am) can be obtained. Finally, complex substrates derived from drug molecules, e.g., *benzocaine*, *dapsone*, *ibuprofen* and *naproxen*, as well as natural products (*lithocholic acid* and *leelamine*) smoothly underwent the BN-isostere benzannulation reaction to deliver the desired products 3ar-3aw in moderate to good yields. It is attractive that a range of functional groups were tolerated with this method. In particular, moieties reactive under various transition-metal catalysis conditions, such as halogens (-F, -Cl, -Br and -I, 3a-3f) and pinacol boronate (3o), remained intact. Electrophilic groups, such as esters (3l and 3ar), amide (3al), and sulfones (3as), as well as Lewis basic groups, such as ethers (3i, 3n, 3v and 3ab), tertiary amines (3j and 3am) and silvl ethers (3au), were also compatible.

Interestingly, apart from simple cyclopropyl, β-phenyl-substituted cyclopropyl imines were also competent substrates (Fig. 4a), delivering 1,2,3,6-tetrasubstituted azaborines **3ax** or **3ay** in moderate yield with complete selectivity of cleaving the more substituted C-C bond. Both the trans and cis isomers of the substrate (1ax) gave the same product (3ax) in comparable yield, suggesting that the reactivity is not significantly affected by the cyclopropane stereochemistry. The relatively low yield was likely due to the steric hindrance of the  $\beta$ -phenyl group during the annulation process. The structure of **3ay** was further confirmed by X-ray crystallography. Note that synthesis of 1,2,3,6-tetrasubstituted azaborines has been very rare<sup>2-6, 26</sup>. Alternatively, such compounds can be prepared more efficiently via site-selective bromination of trisubstituted azaborine 3b followed by cross couplings to introduce various functional groups at the C3 position (Fig. 4b)<sup>26,27,28,29</sup>. To show the synthetic utility of this method, first a BN isostere of a PD-1/PD-L1 inhibitor<sup>30</sup> was synthesized (Fig. 4c). Starting from imine 1az (prepared from the corresponding commercially available ketone and methylamine), the benzannulation with PhBBr<sub>2</sub> provided the 1,2-azaborine intermediate (3az), which then underwent a Pd-catalyzed formylation<sup>31</sup> and reductive amination to deliver the target BN isostere analogue 7. Compound 7 is stable to air and moisture and can be purified via silica gel chromatography. In addition, 1,2-azaborine **3p** can be converted to a BN isostere (8) of an insecticide bifenthrin<sup>32</sup> via a boryl diazo intermediate<sup>33</sup> (3p-CN<sub>2</sub>) in a four-step sequence (Fig. 4d). Note that the aryl group on the boron can be easily converted to a more reactive alkoxy group that can be further transformed to other moieties<sup>34</sup>. Bio-evaluation and pharmacological profiling of these BN-isostere analogues will be carried out in the future. Moreover, a one-pot protocol of preparing 1,2azaborine 3a directly from commercially available cyclopropyl phenyl ketone was realized in good efficiency (Fig. 4e). Finally, the synthesis of 1,2-azaborine **3n** is readily scalable; good yield can be retained in a gram-scale reaction (Fig. 4f).



**Fig. 3** | **Substrate scope.** Reactions were conducted with 0.2 mmol substrate, 0.22 mmol  $R^2BBr_2$ , and 0.02 mmol  $ZnBr_2$  in 1 mL of PhCl at 60 °C under nitrogen. All yields are isolated yields after silica gel chromatography. <sup>a</sup>The reaction was run at 80 °C. TMS, trimethylsilyl.



**Fig. 4** | **Derivatization and synthetic applications. a.** One-step synthesis of 1,2,3,6-tetrasubstituted 1,2-azaborines from disubstituted cyclopropanes. **b.** Synthesis of 1,2,3,6-tetrasubstituted azaborines via derivatization of the 3-bromo-1,2,6-triarylated azaborine. **c.** Synthesis of a BN isostere of the biologically active PD-1/PD-L1 inhibitor. **d.** Synthesis of a BN isostere of insecticide bifenthrin. *o*-Tol, *o*-tolyl. OTf, triflate. **e.** One-pot synthesis from cyclopropyl phenyl ketone. **f.** The gram-scale reaction gave good yield.

**Mechanistic Studies.** To gain some insights into the reaction mechanism, efforts were first put forth to isolate the intermediates from different reaction stages. After imine **1a** reacted with (*o*-tolyl)BBr<sub>2</sub> **2a** in the presence of ZnBr<sub>2</sub> (without adding DBU), the proposed dibromo intermediate **4a** after the C–C cleavage was formed in high yield based on NMR analysis. While **4a** was not isolatable, the corresponding hydrolysis product **4a'** can be purified and fully characterized (Fig. 5a), which suggests intermediacy of such an alkyl bromide in the ring-opening stage. This observation is consistent to a Lewis acid-promoted ring-opening pathway for cyclopropyl imines <sup>35</sup> and our prior understanding of the bromide anion abstraction/ring-opening process in the ArBBr<sub>2</sub>/ZnBr<sub>2</sub> system (Fig. 5d)<sup>24</sup>. When imine **11** was used as the substrate, shortening the DBU treatment time to 1 h led to isolation of a diene intermediate (**51**') in 75% yield along with 8% 1,2-azaborine product **31** (Fig. 5b); in contrast, when the reaction was allowed to stir for 24 h after the addition of DBU, **51**' almost fully disappeared and was converted to 1,2-azaborine **31**. This observation indicates that a diene intermediate, generated via a base-mediated elimination of HBr, is likely involved in the cyclization stage<sup>36,37,38</sup>. As a control experiment, the use of homoallylamine **1ba** 

(mono alkene) as the substrate did not yield any cyclized product under the standard conditions, implying the important role of such a conjugate diene structure in the C–B bond-forming stage (Fig. 5c).




Fig. 5 | Preliminary mechanistic studies. a. The ring-opening intermediate before the addition of DBU is identified. b. The reaction intermediate in the base-mediated cyclization step is identified. c. A control experiment shows the importance of the diene structure in the cyclization stage. d. Proposed mechanism and the energy of the  $6\pi$ -electrocyclization pathway to form 1,2-azaborines. e. Torsion-promoted electrocyclization of intermediate 9, comparing to a triene substrate 11. f. Transition state structures of TS1 and TS2. g. Unique nodal properties of the  $\pi$ -system of intermediate 9 lead to the small energy difference between the symmetry-allowed (TS1) and forbidden (TS2) electrocyclization pathways. DFT calculations were performed at the M06-2X/6-311+G(d,p)/SMD(chlorobenzene)//M06-2X/6-31G(d) level of theory. All energies are with respect to *s-trans*-9.

To understand how 1,2-azaborine is generated from the putative diene intermediate, density functional theory (DFT) calculations were conducted, which support an unusual  $6\pi$ -electrocyclization mechanism (Fig. 5d). The diene intermediate is an isostere of 1,3,5-trienes that are known to undergo  $6\pi$ -electrocyclization; however,  $6\pi$ -electrocyclization of unactivated trienes bearing two terminal substituents

suffers from relatively low reactivity<sup>39,40</sup>. For example, the reaction of triene **11**, the CC isostere of the BN-diene intermediate (9), requires a relatively high activation free energy of 34.9 kcal/mol (Fig. 5e). By contrast, our calculations indicated that diene 9 undergoes a much more facile  $6\pi$ -electrocyclization via TS1 to form cyclic N-borylated iminium 10, which upon DBU-mediated elimination of HBr forms azaborine 3g'. The  $6\pi$ -electrocyclization requires a low activation free energy of 20.8 kcal/mol with respect to the s-trans conformer of 9, which is consistent with the mild reaction conditions observed for the 1,2-azaborine formation. The reactivity of diene 9 is promoted by the polarization of the B–N bond<sup>41,42</sup> as well as the smaller torsional strain to rotate the B-N bond, compared to the rotation of C=C double bond in 1,3,5-trienes, e.g., 11 (Fig. 5e). In TS1, the B-N bond is rotated to a more non-planar geometry, evidenced by the larger dihedral angle of  $\theta$ (C1–N–B–Br) (–52.2°); for comparison, the corresponding dihedral angle of  $\theta$ (C3–C2–C1–Br) (-31.5°) in the 6 $\pi$ -electrocyclization transition state of triene 11 is much smaller. The non-planar geometry of the B-N terminus leads to attractive interactions of the electron-rich dienamine moiety with the vacant B orbital on the borane terminus, as well as reduces the steric repulsions between these two termini in the boat-like transition state (Fig. 5e). Notwithstanding the greater rotation, a smaller torsional energy is required to distort the B-N bond in 9 to the corresponding transition state geometry compared to the rotation of the terminal C=C bond in 11 ( $\Delta E_{\text{torsion}} = 8.8$  and 11.4 kcal/mol for 9 and 11, respectively). As a result, the  $6\pi$ -electrocyclization of diene 9 requires a much lower activation free energy than the corresponding reaction with triene 11 ( $\Delta\Delta G^{\ddagger} = 14.1$  kcal/mol).

It is also remarkable that the  $6\pi$ -electrocyclization can occur through either dis- or conrotatory transition states (**TS1** and **TS2**, respectively, Fig. 5f) that have comparable activation free energies. To the best of our knowledge, there has been no known  $6\pi$ -electrocyclization that allows both dis- and conrotatory pathways. This finding appears to contradict the Woodward–Hoffmann rules, which predict that for  $6\pi$ -electrocyclizations the disrotatory transition state barrier should be significantly lower than the barrier for the conrotatory transition state<sup>43</sup>. However, the alteration of the nodal properties of the HOMO shown in Fig. 5g and S6 indicate that the high polarization of this system eliminates the differences between allowed and forbidden processes, as discussed recently in detail for model systems<sup>44</sup>. The polarization of B–N bond changes the nodal properties of the  $\pi$ -system in **9**. The diminished orbital coefficient on the terminal boron atom of the HOMO of s-*cis*-**9** essentially reduces the preference for the allowed disrotatory (**TS1**) versus the forbidden conrotatory (**TS2**) electrocyclization. In a normal hydrocarbon triene, the orbital overlap between the termini is favorable for the allowed disrotatory process; when one terminal coefficient, i.e., the one of the boron, is nearly zero, as shown in the current system, there is no preference.

#### Conclusions

In summary, we have developed a general, modular, and straightforward method to access diverse multi-substituted monocyclic 1,2-azaborines from readily available staring materials. Owing to the relatively mild conditions, the reaction exhibits a broad substrate scope and good functional group compatibility. This method is expected to greatly simplify syntheses of diverse BN-isostere analogues and to be readily adoptable in medicinal chemistry. The mechanistic insights gained here should have broad implications on boron-mediated electrocyclization for preparing other boron-containing heterocycles.

### References

- <sup>1</sup> Subbaiah, M. A. & Meanwell, N. A. Bioisosteres of the phenyl ring: Recent strategic applications in lead optimization and drug design. *J. Med. Chem.* **64**, 14046-14128 (2021).
- <sup>2</sup> Campbell, P. G., Marwitz, A. J. V. & Liu, S.-Y. Recent advances in azaborine chemistry. *Angew. Chem. Int. Ed.* **51**, 6074–6092 (2012).
- <sup>3</sup> Giustra, Z. X., Liu, S.-Y. The state of the art in azaborine chemistry: new synthetic methods and applications. *J. Am. Chem. Soc.* **140**, 1184-1194 (2018).
- <sup>4</sup> Bhattacharjee, A., Davies, G. H., Saeednia, B., Wisniewski, S. R. & Molander, G. A. Selectivity in the elaboration of bicyclic borazarenes. *Adv. Synth. Catal.* **363**, 2256-2273 (2021).
- <sup>5</sup> Abengózar, A., García-García, P., Fernández-Rodríguez, M. A., Sucunza, D. & Vaquero, J. J. Recent developments in the chemistry of BN-aromatic hydrocarbons. *Adv. Heterocycl. Chem.* **135**, 197-259, (2021).
- <sup>6</sup> Liu, Z. & Marder, T. B. B-N versus C-C: How similar are they? Angew. Chem. Int. Ed. 47, 242-244 (2008).
- <sup>7</sup> Zhao, P., Nettleton, D. O., Karki, R. G., Zécri, F. J. & Liu, S.-Y. Medicinal chemistry profiling of monocyclic 1,2azaborines. *ChemMedChem* 12, 358-361 (2017).
- <sup>8</sup> Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R. & Rice, D. W. A mechanism of drug action revealed by structural studies of enoyl reductase. Science **274**, 2107-2110 (1996).
- <sup>9</sup> Davis, M. C., Franzblau, S. G. & Martin, A. R. Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H<sub>37</sub>R<sub>v</sub> in vitro. *Bioorg. Med. Chem. Lett.* **8**, 843-846 (1998).
- <sup>10</sup> Grassberger, M. A., Turnowsky, F. & Hildebrandt, J. Preparation and antibacterial activities of new 1,2,3diazaborine derivatives and analogs. *J. Med. Chem.* 27, 947-953 (1984).
- <sup>11</sup> Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V. & Xia, Y. Therapeutic potential of boron-containing compounds. *Future Med. Chem.* 1, 1275-1288 (2009).
- <sup>12</sup> Vlasceanu, A., Jessing, M. & Kilburn, J. P. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) Inhibitors. *Bioorg. Med. Chem.* 23, 4453-4461 (2015).
- <sup>13</sup> Marwitz, A. J., Matthews, B. W. & Liu, S.-Y. Boron mimetics: 1, 2-dihydro-1,2-azaborines bind inside a nonpolar cavity of T4 lysozyme. *Angew. Chem. Int. Ed.* 48, 6817-6819 (2009).
- <sup>14</sup> Rombouts, F. J., Tovar, F., Austin, N., Tresadern, G. & Trabanco, A. A. Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example. *J. Med. Chem.* **58**, 9287–9295 (2015).
- <sup>15</sup> Lamm, A. N., Liu, S.-Y. How stable are 1,2-dihydro-1,2-azaborines toward water and oxygen? *Mol. Biosyst.* 5, 1303-1305 (2009).
- <sup>16</sup> Abbey, E. R., Lamm, A. N., Baggett, A. W., Zakharov, L. N. & Liu, S.-Y. Protecting group-free synthesis of 1, 2azaborines: a simple approach to the construction of BN-Benzenoids. *J. Am. Chem. Soc.* **135**, 12908-12913 (2013).
- <sup>17</sup> Dewar, M. J. S. & Marr, P. A. A derivative of borazarene. J. Am. Chem. Soc. 84, 3782-3782 (1962).

- <sup>18</sup> White, D. G. 2-Phenyl-2,1-borazarene and Derivatives of 1,2-Azaboracycloalkanes. J. Am. Chem. Soc. 85, 3634-3636. (1963).
- <sup>19</sup> Ashe, A. J. & Fang, X. A synthesis of aromatic five-and six-membered B-N heterocycles via ring closing metathesis. *Org. Lett.* **2**, 2089-2091 (2000).
- <sup>20</sup> Baggett, A. W., Vasiliu, M., Li, B., Dixon, D. A. & Liu, S. Y., Late-stage functionalization of 1,2-dihydro-1,2azaborines via regioselective iridium-catalyzed C–H borylation: the development of a new N, N-bidentate ligand scaffold. J. Am. Chem. Soc. 137, 5536-5541 (2015).
- <sup>21</sup> Braunschweig, H., Hörl, C., Mailänder, L., Radacki, K. & Wahler, J. Antiaromaticity to aromaticity: from boroles to 1, 2-azaborinines by ring expansion with azides. *Chem. Eur. J.* **20**, 9858–9861 (2014).
- <sup>22</sup> Schäfer, M., Schäfer, J., Dewhurst, R. D., Ewing, W. C., Krahfuß, M., Kuntze-Fechner, M. W., Wehner, M., Lambert, C. & Braunschweig, H. Regioselective catalytic and stepwise routes to bulky, functional-group-appended, and luminescent 1, 2-azaborinines. *Chem. Eur. J.* **22**, 8603-8609 (2016).
- <sup>23</sup> Heß, M., Krummenacher, I., Dellermann, T. & Braunschweig, H. Rhodium-mediated stoichiometric synthesis of mono-, bi-, and bis-1, 2-azaborinines: 1-rhoda-3,2-azaboroles as reactive precursors. *Chem. - Eur. J.* 27, 9503-9507 (2021).
- <sup>24</sup> Lyu, H., Kevlishvili, I., Yu, X., Liu, P. & Dong, G. Boron insertion into alkyl ether bonds via zinc/nickel tandem catalysis. *Science* **372**, 175-182 (2021).
- <sup>25</sup> Fumagalli, G., Stanton, S. & Bower, J. F. Recent methodologies that exploit C–C single-bond cleavage of strained ring systems by transition metal complexes. *Chem. Rev.* **117**, 9404-9432 (2017).
- <sup>26</sup> McConnell, C. R. & Liu, S. Y. Late-stage functionalization of BN-heterocycles. *Chem. Soc. Rev.* 48, 3436-3453 (2019).
- <sup>27</sup> Pan, J., Kampf, J. W. & Ashe, A. J. Electrophilic aromatic substitution reactions of 1,2-dihydro-1,2-azaborines. *Org. Lett.* 9, 679-681 (2007).
- <sup>28</sup> Abengózar, A., García-García, P., Sucunza, D., Frutos, L.M., Castaño, O., Sampedro, D., Pérez-Redondo, A. & Vaquero, J. J. Synthesis, optical properties, and regioselective functionalization of 4a-aza-10a-boraphenanthrene. *Org. Lett.* **19**, 3458-3461 (2017).
- <sup>29</sup> Compton, J. S., Saeednia, B., Kelly, C. B. & Molander, G. A. 3-Boryl-2,1-borazaronaphthalene: umpolung reagents for diversifying naphthalene isosteres. *J. Org. Chem.* **83**, 9484-9491 (2018).
- <sup>30</sup> Guzik, K., Tomala, M., Muszak, D., Konieczny, M., Hec, A., Błaszkiewicz, U., Pustuła, M., Butera, R., Dömling, A. & Holak, T. A. Development of the inhibitors that target the PD-1/PD-L1 interaction—a brief look at progress on small molecules, peptides and macrocycles. *Molecules* 24, 2071 (2019).
- <sup>31</sup> Ying, J. Fu, L. Y. Zhou, C. Qi, X. Peng, J. B. & Wu, X. F. Convenient palladium-catalyzed reductive carbonylation of aryl bromides under gas-free conditions. *Eur. J. Org. Chem.* 2780–2783 (2018).

- <sup>32</sup> Hougard, J. M., Duchon, S., Zaim, M. & Guillet, P. Bifenthrin: a useful pyrethroid insecticide for treatment of mosquito nets. J. Med. Entomol. **39**, 526-533 (2002).
- <sup>33</sup> Liu, Y., Puig de la Bellacasa, R., Li, B., Cuenca, A. B. & Liu, S.Y., 2021. The versatile reaction chemistry of an alphaboryl diazo compound. *J. Am. Chem. Soc.* **143**, 14059–14064 (2021).
- <sup>34</sup> Baggett, A. W. & Liu, S. Y. A boron protecting group strategy for 1,2-azaborines. *J. Am. Chem. Soc.* **139**, 15259–15264 (2017).
- <sup>35</sup> Stevens, R. V. General methods of alkaloid synthesis. Acc. Chem. Res. 10, 193-198 (1977).
- <sup>36</sup> For a seminal work on synthesizing BN-naphthalenes from 2-aminostyrenes, see: Dewar, M. J. S. & Dietz, R. 546. New heteroaromatic compounds. Part III. 2, 1-Borazaro-naphthalene (1,2-dihydro-1-aza-2-boranaphthalene). *J. Chem. Soc.* 2728-2730 (1959).
- <sup>37</sup> Davies, G. H. Zhou, Z. Z. Jouffroy, M. & Molander, G. A. Method for accessing nitrogen-containing, *B*-heteroarylsubstituted 2,1-borazaronaphthalenes. *J. Org. Chem.* 82, 549–555 (2017).
- <sup>38</sup> Liu, X. Wu, P. Li, J. & Cui, C. Synthesis of 1,2-borazaronaphthalenes from imines by base-promoted borylation of C-H bond. *J. Org. Chem.* 80, 3737-3744 (2015).
- <sup>39</sup> Beaudry, C. M. Malerich, J. P. & Trauner, D. Biosynthetic and biomimetic electrocyclizations. *Chem. Rev.* **105**, 4757-4778 (2005).
- <sup>40</sup> Qin, P. Wang, L. A. O'Connor, J. M. Baldridge, K. K. Li, Y. Tufekci, B. Chen, J. & Rheingold, A. L. Transition-metal catalysis of triene 6π electrocyclization: the π-complexation strategy realized. *Angew. Chem. Int. Ed.* **59**, 17958–17965 (2020).
- <sup>41</sup> Guo, Q., Liu, L., Fu, Y. & Yu, T. How to promote sluggish electrocyclization of 1,3,5-hexatrienes by captodative substitution. *J. Org. Chem.* **71**, 6157–6164 (2006).
- <sup>42</sup> Epiotis, N. D. The Theory of Pericyclic Reactions. Angew. Chem. Int. Ed. 13, 751–780 (1974).
- <sup>43</sup> Woodward, R. B. & Hoffmann, R. Stereochemistry of electrocyclic reactions. J. Am. Chem. Soc. 87, 395–397 (1965).
- <sup>44</sup> Kukier, G., Turlik, A., Xue, X. & Houk, K. N. Violations. How nature circumvents the Woodward–Hoffmann rules and promotes the forbidden conrotatory 4n + 2 electron electrocyclization of Prinzbach's vinylogous sesquifulvalene. J. Am. Chem. Soc. **143**, 21694–21704 (2021).

#### Methods

**General procedure for monocyclic 1,2-azaborine synthesis.** An oven-dried 4 mL vial was charged with imine **1** (0.2 mmol, 1 equiv) and ZnBr<sub>2</sub> (4.5 mg, 0.02 mmol, 10 mol%) in a nitrogen-filled glovebox. Dry chlorobenzene (1 mL) was then added. After dibromoborane **2** (0.22 mmol, 1.1 equiv) was added, the vial was tightly sealed and stirred on a pieblock preheated to 60 °C or 80 °C under nitrogen for 4 h. 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU, 90  $\mu$ L, 0.6 mmol, 3 equiv) was then added and the reaction mixture was stirred at the same temperature for 24 h. After cooling to room

temperature, the reaction mixture was filtered through a pad of Celite, washed with ethyl acetate and concentrated to dryness in vacuo. The crude product was subjected to flash column chromatography to give 1,2-azaborine **3**.

## **Data availability**

The data supporting the findings of this study are available within the article and its Supplementary Information. Metrical parameters for the structure of **3ay** is available free of charge from the Cambridge Crystallographic Data Centre (https://www.ccdc.cam.ac.uk/) under reference numbers CCDC 2150659.

## Acknowledgements

This project was supported by University of Chicago, NIGMS (1R21GM144048-01 and R35GM128779), and the National Science Foundation (CHE-1764328). H.L. acknowledges the Suzuki Postdoctoral Fellowship from the University of Chicago. Prof. Viresh Rawal is thanked for thoughtful discussions. DFT calculations were performed at the Center for Research Computing at the University of Pittsburgh and supercomputer resources at NSF XSEDE. Dr. Xin Liu is acknowledged for X-ray crystallography.

## **Author contributions**

H.L. and G.D. conceived and designed the experiments. H.L., Z.C., and Y. W. performed experiments. T.H.T., G.A.K., A.T., K.N.H., and P.L. designed and conducted the density functional theory calculations. H.L., T.H.T., K.N.H., P.L. and G.D. wrote the manuscript. P.L. and G.D. directed the research.

# **Competing interests**

A provisional patent application of this work has been filed.

### **Additional information**

Supplementary information The online version contains supplementary material available.

Correspondence and requests for materials should be addressed to K.N.H., P.L. or G.D.